Whitfield Assists Alebund on its Hong Kong IPO
Overview
Alebund Pharmaceuticals listed in Hong Kong on June 29, 2026, under code 9637, according to the source announcement concerning the sponsors' representation.
Offering terms
The company offered 56,755,400 H-shares at HK$22.60, raising approximately HK$1.28 billion before additional allotments.
Sponsors and investors
Jefferies Hong Kong, Merrill Lynch Asia Pacific and Huatai Financial Holdings Hong Kong were joint sponsors. Eleven cornerstone investors committed an aggregate US$81.5 million.
Business and advisers
Alebund develops renal therapies. The source credits capital markets advisers Mengyu Lu, George Zheng, Yuchen Han and Jingwen Dong for the flotation.
